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The present study investigated the usefulness of bronchoalveolar (BAL) fluid cytology in the identification of non- 
infectious pulmonary conditions in patients hospitalized in the intensive care unit (ICU) and suspected of 
pneumonia. A total of 182 BAL fluid samples obtained during a 27-month period from 130 ICU patients with 
suspected pneumonia were quantitatively cultured and investigated for opportunistic pathogens. Cytocentrifuged 
preparations stained with the May-Grtinwald Giemsa and Perls’s methods were reviewed. A non-infectious 
aetiology was considered when cultures yielded micro-organisms in quantities < lo3 colony-forming units (CFU) 
per ml, in the absence of any other pathogen and in conjunction with one or more of the following cytological 
findings: >20% haemosiderin macrophages, > 10% lymphocytes, the presence of activated lymphocytes, plasma 
cells, > 5% eosinophils, a preponderance of foamy macrophages, reactive type II pneumocytes or malignant cells. 
Patients’ clinical records were reviewed to identify a clinical diagnosis for these episodes. 
In thirty-five (19.2%) BAL fluid samples from 26 patients, the cytological findings pointed to a non-infectious 
origin. An alternative diagnosis was ascertained in 20 of 26 patients. Diagnoses included: drug-induced pneumonitis 
(n = 7), aspiration of gastric contents (n = 2), pulmonary emboli (n = 3), adult respiratory distress syndrome (n = 4), 
lung contusion (n = l), cardiogenic pulmonary oedema (n = l), and carcinomatous lymphangitis (n = 2). The BAL 
fluid cytological findings were readily discernable and proved to be useful in the diagnostic work-up of samples 
obtained from ICU patients with suspected pneumonia. 
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Introduction 
Pneumonia is common in patients in intensive care 
units (ICUs), especially in mechanically ventilated 
patients. Establishing the diagnosis of pneumonia in these 
patients is notoriously difficult as clinical and radiological 
parameters offer a high sensitivity at the cost of an 
unacceptably low specificity (1). Adding the results of 
quantitative cultures of bronchoalveolar lavage (BAL) fluid 
increases the diagnostic specificity (2) but preliminary 
and definitive culture results take 24 h and up to 72 h, 
respectively. 
Apart from infectious pneumonia, a number of non- 
infectious pulmonary conditions may explain the clinical 
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symptoms of the ICU patient with suspected pneumonia. 
Such conditions include pulmonary haemorrhage, malig- 
nancy, drug-induced toxicity, the adult respiratory distress 
syndrome (ARDS) and cardiogenic pulmonary oedema. It 
is important to distinguish these conditions from pneumo- 
nia as the management and prognosis of these entities is 
quite different (3,4). Distinctive findings in BAL fluid 
cytology, such as lymphocytosis, the presence of activated 
lymphocytes, plasma cells and eosinophils or the prepon- 
derance of foamy macrophages point to drug-induced 
pulmonary disease (5,6), and the presence of reactive type 
II pneumocytes has been described in association with 
ARDS (7). BAL fluid cytological findings in ARDS are 
characterized by a marked predominance of neutrophils in 
the early phase and a recruitment of macrophages, 
lymphocytes and eosinophils in the late phase (8). A 
number of >20% haemosiderin macrophages has been 
demonstrated to be indicative for alveolar haemorrhage (9). 
Until now, however, the usefulness of BAL fluid cytology 
in the diagnosis of these non-infectious pulmonary condi- 
tions in ICU patients has received little attention in the 
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literature. In daily practice, the use of BAL fluid cytology is 
limited to the enumeration of infected cells and to the 
identification of squamous epithelial cells which are 
indicative of oropharyngeal contamination (10,ll). 
In our hospital, bronchoscopy with BAL is routinely 
used in the diagnosis of pneumonia in the ICU setting (2). 
Recently, we introduced a standardized protocol for the 
cytocentrifugation process and included the differential cell 
count as part of the routine microbiological work-up of 
BAL fluid specimens. As we collected a series of 
consecutive BAL fluid samples performed in ICU patients 
with suspected pneumonia, we decided to evaluate the 
usefulness of BAL fluid cytology in the prediction of non- 
infectious pulmonary conditions. We therefore retrospec- 
tively looked for the diagnosis in those BAL fluid samples 
that showed cytological findings consistent with a non- 
infectious condition. 
Materials and Methods 
STUDY POPULATION 
Over a 27-month period (January 1996 to April 1998), BAL 
fluid samples from ICU patients in the University Hospital 
Maastricht were obtained. All patients were suspected of 
having pneumonia as defined by clinical and radiological 
criteria (2). 
SAMPLING TECHNIQUE 
A fiber-optic bronchoscope (Pentax FB-lSH/FB- 15X, 
Pentad Medicals, Tokyo, Japan) was introduced through 
a special adaptor (Swivel Connector, Gibeck Respiration, 
Upplands V&by, Sweden) and ‘wedged’ into the 
affected segmental or subsegmental bronchus. The 
fluid was instilled into the subsegment through the biopsy 
channel of the bronchoscope in four aliquots of 50 ml 
sterile saline (0.9% NaCl, room temperature) and 
immediately aspirated and recovered. The BAL fluid 
samples were transported to the laboratory within 1.5 min 
of collection and analysed within 1 h of arrival in the 
laboratory. 
PROCESSING OF BAL FLUID SPECIMENS 
The volume of the recovered BAL fluid was recorded. The 
first fraction, representing the bronchial fraction, was 
separated for mycobacterial culture and the remaining 
fractions were pooled for further analysis. The total cell 
count was performed in a FuchsRosenthal haemocyt- 
ometer chamber. BAL fluid samples were quantitatively 
cultured for bacteria and yeasts by means of a calibrated 
loop technique (12). They were also cultured for filamen- 
tous fungi and mycobacteria and, if clinically indicated, for 
viruses and Legionella spp. In addition, stains for detection 
of Pneumocystis carinii and Legionella pneumophiia (im- 
munofIuorescent monoclonal antibody stainings), filamen- 
tous fungi (Methenamine-silver stain) and acid-fast bacteria 
(auramine-rhodamine stain) were performed on cytocen- 
trifuged preparations. When a community-acquired pneu- 
monia was suspected, serology for detection of viral 
pathogens was done and polymerase chain reactions for 
detection of Chlamydia pneumoniae and Mycoplasma 
pneumoniae were performed. 
Cytocentrifugation was done with the Cytospin 
3 apparatus (Shandon Scientific Ltd, Astmoor, U.K.) 
as previously described (13). Differential cell counts 
were made on May-Grtinwald Giemsa (MGG) stained 
preparations, by the first or second author examining 
500 nucleated cells. Both macrophages and neutrophils 
were screened for the presence of intracellular organisms 
and the number of infected cells was expressed as 
a percentage of the 500-cell aliquot counted. The 
preparations were sealed (Xylene substitute mountant, 
Shandon) and stored at room temperature. When baso- 
philic granules were seen in macrophages or polymorpho- 
nuclear cells, Perls’ stain for haemosiderin visualization was 
performed (14). 
REJECTION CRITERIA 
BAL fluid samples were excluded if the retrieved volume 
was less than 20 ml, if the cytocentrifuged preparations 
showed excessive amounts of red blood cells, intercellular 
debris or damaged nucleated cells, or if the differential cell 
count yielded 1% squamous epithelial cells or 2 5% 
ciliated cells. 
DEFINITION 
BAL fluid samples were categorized into four groups based 
on the following diagnostic criteria. 
Group I, pneumonia microbiologically confirmed: 
this group consisted of samples for which quantitative 
cultures yielded micro-organisms in quantities >104 colony 
forming units per millilitre (cfu ml-‘), or for which an 
obligatory respiratory pathogen such as P. carinii was 
demonstrated. 
Group II, pneumonia not conclusive: BAL fluid samples 
were categorized as “not conclusive” when they had 
borderline quantitative culture results, i.e. counts 2 lo3 
and < IO4 cfu ml-‘. 
Group III, pneumonia excluded, no cytological abnorm- 
alities: infectious pneumonia was considered as microbio- 
logically excluded at a culture threshold of < lo3 cfu ml-’ 
and < 2% infected cells, and with no obligatory respiratory 
pathogen demonstrated. On cytological examination of the 
BAL fluid, none of the findings cited for Group IV was 
observed. 
Group IV pneumonia excluded, non-infectious aetiology: 
BAL fluid samples were considered as of ‘non-infectious 
etiology’ when pneumonia was microbiologically excluded 
(criteria as for Group III) in the absence of previous (within 
72 h) antimicrobial therapy and when one or more of the 
following cytological findings were observed: the presence 
of malignant cells, a count of > 10% lymphocytes, a count 
of > 5% eosinophils, the presence of activated lymphocytes 
or plasma cells and the preponderance of foamy macro- 
phages. Moreover, a number of > 20% haemosiderin laden 
macrophages was considered as diagnostic for alveolar 
haemorrhage (9). 
REVIEW OF CLINICAL RECORDS 
The patients’ clinical records were reviewed for clinical, 
radiological and laboratory evidence to identify diagnoses 
of non-infectious aetiology. 
Results 
During the study period, 1721 patients were admitted to the 
ICU and 228 bronchoscopies with BAL were performed 
(Fig. 1). Forty-six BAL fluid samples were excluded from 
analysis, resulting in 182 BAL fluid samples obtained from 
130 patients. 
Seventy-seven BAL fluid samples were considered as 
microbiologically proved pneumonia and allocated to 
Group I. L. pnewnophila was identified as the pathogen 
in one BAL fluid sample, P. carinii in four BAL fluid 
samples (three patients) and a viral pneumonia was 
detected in three BAL fluid samples obtained in two 
patients (RSV and para-influenza virus, respectively). At a 
threshold of lo4 cfu ml-‘, infectious pneumonia was 
further confirmed in 69 BAL fluid samples. Group II 
(pneumonia not conclusive) consisted of 23 BAL fluid 
samples and 47 BAL fluid samples were included in Group 
III (pneumonia microbiologically excluded, no cytological 
abnormalities). 
Based on the exclusion of a microbiological pathogen 
and on the presence of one or more of the cytological 
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findings, 35 BAL fluid samples were assigned to Group IV 
(‘non-infectious etiology’). These 35 BAL fluid samples 
accounted for 19.2% of the 182 included BAL fluid samples 
and were obtained from 26 (20%) of 130 patients (nine 
patients underwent repeat bronchoscopy with BAL). 
Table 1 lists the non-infectious conditions identified by 
review of the clinical records in the 26 patients and the 
differential cell counts together with the cytological findings 
in the corresponding BAL fluid samples. 
The patients’ mean age was 62.8 Z!Z 14.2 years, and the 
male to female ratio 1.36,: 1. Half (13) of the patients were 
admitted from the community, one patient was admitted 
from a nursing home and 12 were transferred from another 
hospital ward. 
Bronchoscopy was performed after 11.2 f 13.9 days of 
ICU admission (range 1-57 days), with seven BAL fluid 
samples obtained on the day of the patient’s admission to 
the ICU. Twenty-six of 35 BAL fluid samples were 
obtained from ventilated patients; in 21 samples the patient 
was ventilated for more than 72 h prior to suspicion of 
pneumonia. For two BAL fluid samples, no data on 
ventilation were retrieved upon chart review. 
Three patients demonstrated amiodarone-induced pneu- 
monitis, which was confirmed histologically in one case. 
Nortriptyline pulmonary toxicity was observed after an 
accidental overdose in a psychiatric patient. Carbamaze- 
pine-induced pneumonitis occurred due to self-poisoning. 
Methotrexate-induced pneumonitis occurred in a patient 
treated because of rheumatoid arthritis. Melloquine-in- 
duced pneumonitis was seen in a patient with hemizygote 
glucose-6-phosphate-dehydrogenase deficiency. Aspiration 
of gastric contents was documented in a patient during 
surgical treatment for achalasia and in another patient 
who aspirated enteral feeding during a prolonged ICU 
1721 ICU admissions in a 27-month period 
1 
228 BALs performed in 161 patients 
1 46 BALs in 31 patients excluded 
182 BALs in 130 patients included 
/------ 
Pneumonia microbiologically confirmed 
77 BALs in 68 patients* 
Group II 
Diagnosis of pneumonia not conclusive 
23 BALs in 23 natienta* 
Group I 
Pneumocystis carinii 
Legionella pneumophila 
Viral pneumonia 
Bacteria < IO4 cfu ml-’ and 2 lo3 cfu ml- 
Bacteria 2 lo4 CPU/ml-’ 
Group III 
Pneumonia microbiologically excluded ** 
No cytological abnormahties 
47 BALs in 43 patients* 
Group IV 
Pneumonia microbiologically excluded ** 
Cytological evidence pointing to a 
non-infectious origin 
35 BALs in 26 patients* 
Diagnosis of non-infectious origin ascertained 
30 BALs in 20 patients 
FIG. 1. Flow chart of BAL fluid selection and definitions. *Numbers exceed the total number of patients included ‘as several 
patients underwent repeat bronchoscopy with BAL. **Bacteria < 103/ml-’ and ~2% cells containing intracellular ’ 
organisms. 
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stay. Pulmonary emboli were found at autopsy in two 
patients and a third patient developed multiple pulmonary 
emboli after surgical revision of a hip prosthesis. Based 
on respiratory parameters and a clinical picture, the 
diagnosis of ARDS was assessed in four patients; in one 
of them the diagnosis was confirmed on histological 
examination at post-mortem. Numerous iron-laden macro- 
phages were seen in one patient with lung contusion and in 
another patient with severe cardiogenic pulmonary oede- 
ma. Malignant cells originating from a disseminated lung 
adenocarcinoma were seen in two patients; in one of them, 
the BAL fluid cytology findings provided the first suspicion 
of malignancy. 
Overall, in seven patients the aetiological diagnosis was 
established by histology obtained by biopsy or autopsy and 
in 13 patients the diagnosis was supported by clinical, 
radiological and laboratory findings. In the six remaining 
patients, data regarding the clinical status were not 
conclusive. 
Discussion 
Based upon the absence of a microbiological pathogen and 
upon cytological evidence present in MGG-stained cyto- 
centrifuged preparations, in this study we classified 35/182 
(19.2%) BAL fluid samples as of non-infectious origin. 
These BAL fluid samples were obtained in 26 ICU patients 
with suspected pneumonia. Retrospectively, we identified a 
diagnosis explaining the non-infectious condition in 20 of 
the 26 patients. 
We realize that one of the major limitations of this study 
was its retrospective design. This design did not allow 
tracing of all cases of non-infectious lung conditions. As the 
use of antimicrobial agents prior to bronchoscopy was not 
systematically documented, reliable exploration of Group 
II (pneumonia not conclusive, BAL fluids with borderline 
quantitative culture results) and Group III (pneumonia 
excluded, no cytological abnormalities) was not possible. 
Neither were we able to identify a diagnosis in all non- 
infectious BAL fluid samples. In particular, difficulties were 
encountered in the retrospective diagnosis of ARDS and 
drug-induced pneumonitis. In the case of a suspected drug- 
induced pneumonitis, a definite role for a particular drug 
can not be proven in the absence of rechallenge. In the 
present series, rechallenge supported the diagnosis of 
carbamazepine-induced toxicity as the patient was re- 
admitted with a second auto-intoxication. The role of 
mefloquine was confirmed by restarting of the drug prior to 
the drug being suspected. Both cases have been described 
elsewhere in detail (15,16). Among others, amiodarone, 
methotrexate and anti-depressants are known to be capable 
of causing drug-induced pneumonitis (17-19). In the cases 
presently described, these drugs were considered as 
causative because withdrawal of the drug resulted in 
clinical and radiological improvement. 
Reviewing a large number of studies, Timsit et al. 
concluded that about two-thirds of the episodes of 
suspected pneumonia in ventilated patients do not meet 
quantitative culture criteria but are related to other 
conditions. The authors however admitted that no data 
definitely supported their conclusion, as many of these 
episodes were believed to be false-negative pneumonias in 
which bacterial growth was suppressed by the administra- 
tion of antimicrobial agents prior to bronschoscopy (20). In 
view of their supposition, it is striking that few studies list 
an alternative diagnosis for those episodes with no 
microbiological evidence of pneumonia (3,4,21,22). The 
reported incidences of non-infectious conditions in these 
studies were higher than in the present study, but non- 
infectious BAL fluid samples were defined at a culture 
threshold of < lo4 CFU ml-’ , whereas in the present 
study a threshold of < lo3 CFU ml-’ was applied to 
exclude BAL fluid samples with borderline quantitative 
culture results. The low culture threshold in the present 
study was combined to a threshold for infected cells of 2%, 
which is the lowest cited cutoff value (23). By using these 
stringent criteria, we aimed to minimise the diagnosis of 
false-negative infectious pneumonia but probably may have 
underestimated the number of non-infectious conditions. 
Second, the authors of previous studies looked for 
alternative diagnoses in all non-infectious BAL fluid 
samples, irrespective of the BAL fluid cytological findings. 
In this way, their alternative diagnoses included more cases 
of atelectasis, pleural involvement and pulmonary oedema, 
which are conditions for which, to our knowledge, no 
specific cytological BAL fluid findings have been described. 
Although the present study did not intend to search an 
alternative diagnosis in Groups II and III, we assume that 
conditions such as atelectasis and pleural involvement may 
have been present in at least part of these episodes. The 
exact incidences and nature of the non-infectious condi- 
tions in this setting should however be addressed by a 
prospective study. 
In contrast to previous studies, we added the findings of 
the cytological examination to direct the investigation to a 
non-infectious condition. Retrospectively, we were able to 
demonstrate an alternative diagnosis for infectious pneu- 
monia in 20 (77%) out of the 26 patients that were selected 
based on well-defined cytological criteria. Most microbio- 
logical laboratories are reluctant to perform BAL differ- 
ential cell counts as these counts are not always 
unequivocal (24) and cannot differentiate bronchial infec- 
tion from lung infection (25). Moreover, performing BAL 
fluid differential cell counts requires skilled microscopists 
and is looked upon as labourious and time-consuming in 
times of limited sources and tendencies to automation. The 
cytological findings looked for in the present study are, 
however, easily discernable on MGG-stained cytocentri- 
fuged preparations. The processes of cytocentrifugation, 
MGG staining and cell differentiation as described here can 
be achieved within a 2-h period, making the results of the 
BAL fluid cytology available within a very short delay. The 
MGG stain (or an equivalent one) with the differential cell 
count can be conveniently incorporated into the routine 
microbiological work-up of BAL fluid samples. Other 
advantages of the MGG stain are its ability to detect P. 
carinii (12) and its reliability for enumeration of intracel- 
lular organisms (13). The sensitivity of the cytological 
findings for the detection of a non-infectious origin, 
together with the feasibility and the low turn-over time of 
the procedure, lead us to recommend BAL fluid cytology as 
part of the routine work-up in cases of ICU patients with 
suspected pneumonia. 
One should note that the cytological findings under 
consideration are not pathognomonic. They point to the 
possibility of a non-infectious condition which has to be 
confirmed and identified by clinical, radiological or 
laboratory findings. In our experience, the above-listed 
cytological findings were not specific for the non-infectious 
BAL fluid samples. In this way, we also observed alveolar 
haemorrhage in seven of the 69 bacterial pneumonias, in 
agreement with the association between alveolar haemor- 
rhage and infection reported by others (9). Moreover, seven 
of the patients in whom a non-infectious aetiology was 
diagnosed developed a pneumonia during their further ICU 
stay. In BAL fluid samples from patients with P. carinii 
pneumonia, we occasionally observed foamy macrophages 
and plasma cells similar to cases of drug-induced toxicity 
(unpublished observations) and we have noted elevated 
numbers of lymphocytes in BAL fluids obtained from 
patients with tuberculosis, in line with the findings of others 
(26,27). These observations emphasize the importance of a 
thorough microbiological investigation, even if BAL fluid 
cytology at first glance points to a non-infectious condition. 
Further, it should be noted that the presence of foamy 
macrophages in the case of amiodarone intake may 
represent amiodarone-impregnation and do not necessarily 
imply toxicity (6). 
From Table 1, it is clear that, apart from malignancy, 
none of the cytological findings was confined to a particular 
non-infectious aetiology. This may partly be explained by 
an overlap between the distinct conditions, i.e., both lung 
contusion and aspiration of gastric contents are we&known 
risk factors for the development of ARDS (28) and non- 
infectious processes may co-exist with pneumonia (29). It is 
clear that the discriminative power of the cytological 
findings will be augmented if the number of BAL fluid 
samples included for comparison increases. For this reason, 
we are presently conducting a prospective study that will 
investigate the predictive value of the different cytological 
parameters and their combinations. 
In conclusion, the present study demonstrated the value 
of the BAL fluid cytological findings for the diagnosis of 
non-infectious conditions jn ICU patients with suspected 
pneumonia. We recommend incorporating BAL fluid 
cytology as part of the routine work-up of BAL fluid 
samples obtained in the ICU setting. A prospective study 
should address the exact incidence and aetiologies of non- 
infectious pulmonary conditions in the ICU setting and 
allow refinement of the cytological description. In this way, 
cytology may further improve the diagnostic accuracy of 
BAL fluid analysis in ICU patients with suspected 
pneumonia. 
Acknowledgement 
The authors thank Dr J. Tjhie for performing the PCR 
analysis. 
References 
1. Johanson WG Jr, Seidenfeld JJ, Gomez P, Los Santos 
de R, Coalson JJ. Bacteriologic diagnosis of 
nosocomial pneumonia following prolonged 
mechanical ventilation. Am Rev Respir Dis 1988; 137: 
259-264. 
2. Bonten MJM, Bergmans DCJ, Stobberingh EE, et al. 
Implementation of bronchoscopic techniques in the 
diagnosis of ventilator-associated pneumonia to reduce 
antibiotic use. Am J Respir Crit Care Med 1997; 156: 
1920-1924. 
3. Guerra LF, Baugham RP. Use of bronchoalveolar 
lavage to diagnose bacterial pneumonia in mechani- 
cally ventilated patients. Crit Cure Med 1990; 1S: 16% 
172. 
4. Timsit JF, Misset B, Goldstein FW, Vaury P, Carlet J. 
Reappraisal of distal diagnostic testing in the diagnosis 
of ICU-acquired pneumonia. Chest 1995; 108: 1632- 
1639. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
Drent M, van Velzen-Blad H, Diamant M, Wagenaar 
Sj SC, Donkerwolcke-Bogaert M, van den Bosch 
JMM. Differential diagnostic value of plasma cells 
in bronchoalveolar lavage fluid. Chest 1993; 103: 
1720-1724. 
Rosenow EC III, Martin WJ II. Drug-induced inter- 
stitial lung disease. In: Schwarz MI, King TE (eds). 
Interstitial Lung Disease. 2nd edn, 1993: 255-270. 
Grotte D, Stanley MW, Swanson PE, Henry-Stanley J, 
Scott D. Reactive Type II pneumocytes in bronchoal- 
veolar lavage fluid from adult respiratory distress 
syndrome can be mistaken for cells of adenocarcinoma. 
Diagn. Cytopathol. 1990; 6: 317-322. 
Nakos G, Kitsiouli EL, Tsangaris L, Lekka MD. 
Bronchoalveolar lavage fluid characteristics of early 
intermediate and late phases of ARDS. Intensive Care 
Med 1988; 24: 296-303. 
Lassence de A, Fleury-Feith J, Escudier E, Beaune J, 
Bernaudin JF, Cordonnier C. Alveolar hemorrhage. 
Diagnostic criteria and results in 194 immunocompro- 
mised hosts. Am J Respir Crit Care Med 1995; 151: 
157-163. 
Kahn FW, Jones JM. Diagnosing bacterial respiratory 
infection by bronchoalveolar lavage. J Infect Dis 1987; 
155: 8624369. 
Chastre J, Fagon JY, Soler P, et al. Quantification of 
BAL cells containing intracellular bacteria rapidly 
identifies ventilated patients with nosocomial pneumo- 
ma. Chest 1989; 95: 19OS-192s. 
Baselski VS, El-Torky M, Coalson JJ, Griffin JP. The 
standardization of criteria for processing and inter- 
preting laboratory specimens in patients with suspected 
ventilator-associated pneumonia. Chest 1992; 102: 
s571-s579. 
De Brauwer EIGB, Jacobs JA, Nieman FH, Brugge- 
man CA, Drent M. Test characteristics of Acridine 
Orange, Gram and May-Griinwald Giemsa stains 
for the detection of intracellular organisms in bronch- 
oalveolar lavage fluid. J Clin Microbial 1999: 37: 
427429. 
578 J. A. JACOBS ETAL. 
14. Dacie JV, Lewis SM (eds). Practical Haematology. 6th 
Edition. Edinburgh: Churchill Livingstone 1984. 
15. Wilschut FA, Cobben NAM, Thunissen FBJM, 
Lamers RJS, Wouters EFM, Drent M. Acute inter- 
stitial pneumonitis due to single overdose with carba- 
mazepine. Eur Respir J 1997; 10: 2163-2165. 
16. Drent M. Drug-induced pneumonia associated with 
hemizygote glucosed-phosphate dehydrogenase defi- 
ciency. Eur J Haematol 1998; 61: 218-220. 
17. Cooper AD, White DA, Matthay RA. Drug-induced 
pulmonary disease. Part 1: cytotoxic drugs. Am Rev 
Respir Dis 1986; 133: 321-340. 
18. Cooper AD, White DA, Matthay RA. Drug-induced 
pulmonary disease. Part 2: noncytotoxic drugs. Am Rev 
Respir Dis 1986; 133: 4888505. 
19. Hubbard R, Venn A, Smith C, Cooper M, Johnston I, 
Britton J. Exposure to commonly prescribed drugs and 
the etiology of cryptogenic fibrosing alveolitis. Am J 
Respir Crit Care Med 1998; 157: 743-747. 
20. Timsit JF, Chevret S, Valcke J, Misset B, Renaud B, 
Goldstein FW, Vaury P, Carlet J. Mortality of 
nosocomial pneumonia in ventilated patients: influence 
of diagnostic tools. Am J Respir Crit Care Med 1996; 
154: 116-123. 
21. Aubas S, Aubas P, Capdevila X, Darbas H, Roustan J- 
P, du Cailar J. Bronchoalveolar lavage for diagnosing 
bacterial pneumonia in mechanically ventilated pa- 
tients. Am J Respir Crit Care Med 1994; 149: 860-866 
22. Meduri GU, Mauldin GJ, Wunderink RJ, et al. Causes 
of fever and pulmonary densities in patients with 
clinical manifestations of ventilator-associated pneu- 
monia. Chest 1994; 106: 221-233. 
23. Allaouchiche B, Jaumain H, Dumontet C, Motin J. 
Early diagnosis of ventilator-associated pneumonia. Is 
it possible to define a cutoff value of infected cells in 
BAL fluid? Chest 1996; 110: 1158-l 165. 
24. Baughman RP, Strohofer S, Kim CK. Variation of 
differential cell counts of bronchoalveolar lavage fluid. 
Arch Path01 Lab Med 1986; 110: 341-343. 
25. Thorpe JE, Baughman RP, Frame PT, Wesselet TA, 
Staneck JL. Bronchoalveolar lavage for diagnosing 
acute bacterial pneumonia. J Infect Dis 1987; 155: 855- 
861. 
26. Baughman RP, Dohn MN, London RG, Frame PT. 
Bronchoscopy with bronchoalveolar lavage in tubercu- 
losis and fungal infections. Chest 1991; 99: 92-97. 
27. Drent M, Wagenaar Sj SC, Mulder PHC, Velzen-Blad 
van H. Bronchoalveolar lavage fluid profiles in 
sarcoidosis, tuberculosis, non-Hodgkin’s and Hodg- 
kin’s disease: an evalutaion of differences. Chest 1994; 
105: 514-520. 
28. Steinberg KP, Milberg JA, Martin TR, Mauncer RJ, 
Cockill BA, Hudson LD. Evolution of bronchoalveolar 
cell population in the adult respiratory distress syn- 
drome. Am J Respir Crit Care Med 1994; 150: 113-122. 
29. Marquette CH, Copin M-C, Wallet F, et al. Diagnostic 
tests for pneumonia in ventilated patients: prospective 
evaluation of diagnostic accuracy using histology as a 
diagnostic gold standard. Am J Respir Crit Care Med 
1995; 151: 1878-1888. 
